Published on 01 January 2018

Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy

View Dataset
GlaxoSmithKline

Description

The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 12-13 years who were vaccinated with four doses of Infanrix™-Hexa in infancy and to assess the anamnestic response, immunogenicity, safety and reactogenicity of a single challenge dose of the hepatitis B vaccine Engerix™-B Kinder.

Citations (0)

Mentions (0)

Metrics

Dataset Index

0.8

FAIR Score

31%

Citations

0

Mentions

0

Metrics Over Time

Publication Details

DOI

Publisher

Vivli

Assigned Domain

Subfield

Epidemiology

Field

Medicine

Domain

Health Sciences

Confidence Score

50%

Source

Scholar Data Model

Keywords

Conditions: Hepatitis BInterventions: Engerix™-B Kinder

Normalization Factors

FT

13.46

CTw

1.00

MTw

1.00